Withings Heart Function Risk Notification Retrospective Study (HFRN)

June 12, 2026 updated by: Withings

Validation of the Withings Heart Function Risk Notification (HFRN): A Retrospective Study of Diagnostic Performance for Heart Failure Detection in US Consumer Smart-Scale Users

This is a fully decentralized retrospective, non-interventional study evaluating the diagnostic performance of the Withings Heart Function Risk Notification (HFRN), a software-only medical device (SaMD) that analyzes longitudinal weight / BMI, body-water-percent variability, and activity (step) data collected passively by Withings connected smart scales and the Withings activity-tracking ecosystem. The study estimates Sensitivity (Se) and Specificity (Sp) of HFRN against a US claims-based (HealthVerity) heart-failure reference standard, evaluated on a pre-specified holdout test set. The findings support a 510(k) substantial-equivalence determination to the predicate Viz HCM (DEN230003) within the Cardiovascular machine learning-based notification software generic type (21 CFR 870.2380).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a fully decentralized retrospective study. Data were collected passively between 2020 and 2025 from consumer users of commercially available Withings devices in their home environments. There are no physical study sites and no in-person visits.

Study Type

Observational

Enrollment (Estimated)

9000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Île-de-France Region
      • Issy-les-Moulineaux, Île-de-France Region, France, 92130
        • Withings (Sponsor) - Decentralized Retrospective Study, No Physical Sites

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Adult US consumer users (>= 45 years) of Withings connected smart scales (Body Cardio, Body Scan, Body Comp) with a source of step counts synced into the Withings ecosystem and successful linkage to US HealthVerity administrative claims, enabling heart-failure ground-truth ascertainment and covariate analyses. The development dataset comprises 54,717 individuals (52,736 controls and 1,981 HF cases). The pre-specified holdout test set comprises 9,093 individuals (8,548 controls and 545 HF cases), with case/control mix calibrated to the 2021 NHANES-estimated HF prevalence for US adults >= 45 years.

Description

Inclusion Criteria:

  • Users of commercially purchased, consumer-grade Withings smart scales (e.g. Body Cardio [WBS04], Body Scan [WBS08], Body Comp [WBS12 / WBS12C]) used in a standard home environment
  • A source of step counts synced into the Withings ecosystem (a Withings activity tracker, a smartphone, or a third-party activity tracker)
  • US HealthVerity claims linkage available, enabling heart-failure ground-truth ascertainment
  • Age >= 45 years
  • At least one 13-week quarter in which at least one of the three quarterly features (mean BMI, standard deviation of body-water percent, 90th-percentile daily steps) can be computed

Exclusion Criteria:

  • Users for whom heart-failure status cannot be determined from claims (unknown label; e.g. controls with < 2 years of continuous enrollment)
  • Users with no usable measurement after per-reading plausibility screening (weight outside 20-400 kg, BMI outside 10-60 kg/m2, body-water percent outside 40-80%, daily steps outside 0-100,000, height outside 100-250 cm, or age outside 45-120 years)
  • Users without an individual Withings account (shared accounts excluded to prevent data contamination)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HF Cases
Withings smart-scale users with US HealthVerity claims linkage who meet the claims-based heart-failure case definition (>= 1 inpatient HF ICD-10 code, or >= 2 distinct outpatient-visit HF ICD-10 codes; per the first-match-wins claims algorithm). Holdout test set: 545 HF cases.
Software-only medical device (SaMD): an algorithm that analyzes quarterly-aggregated features computed from data passively captured by Withings connected smart scales and step counts synced into the Withings activity-tracking ecosystem. When the predicted heart-failure risk probability exceeds a calibrated decision threshold, the device emits a notification directing the user to seek confirmatory clinical evaluation. The notification is non-diagnostic.
Ground-truth heart-failure case / control status derived from US HealthVerity administrative claims by a deterministic, pre-specified rule set. Per-user features (counts of HF ICD-10 codes split by inpatient vs. distinct outpatient visits, continuous-enrollment duration, supporting CPT and laboratory evidence) are passed through an ordered first-match-wins classifier. Each user is additionally assigned a claims-operationalized ACC/AHA heart-failure stage (0 / A / B / C). Adjudication is fully automated; no clinician adjudication is performed.
Control
Withings smart-scale users with US HealthVerity claims linkage who meet the claims-based control definition (>= 2 years of continuous enrollment, no heart-failure ICD-10 evidence). Holdout test set: 8,548 controls. Case/control mix is calibrated to the 2021 NHANES-estimated heart-failure prevalence for US adults >= 45 years.
Software-only medical device (SaMD): an algorithm that analyzes quarterly-aggregated features computed from data passively captured by Withings connected smart scales and step counts synced into the Withings activity-tracking ecosystem. When the predicted heart-failure risk probability exceeds a calibrated decision threshold, the device emits a notification directing the user to seek confirmatory clinical evaluation. The notification is non-diagnostic.
Ground-truth heart-failure case / control status derived from US HealthVerity administrative claims by a deterministic, pre-specified rule set. Per-user features (counts of HF ICD-10 codes split by inpatient vs. distinct outpatient visits, continuous-enrollment duration, supporting CPT and laboratory evidence) are passed through an ordered first-match-wins classifier. Each user is additionally assigned a claims-operationalized ACC/AHA heart-failure stage (0 / A / B / C). Adjudication is fully automated; no clinician adjudication is performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Sensitivity (Se) and its 95% CI of the HFRN algorithm for heart-failure detection, evaluated on the pre-specified holdout test set.
Time Frame: 13 weeks
13 weeks
Specificity (Sp) and its 95% CI of the HFRN algorithm for heart-failure detection, evaluated on the pre-specified holdout test set.
Time Frame: 13 weeks
13 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Pierre Escourrou, MD, PhD, Centre Interdisciplinaire du Sommeil, Paris, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

June 12, 2026

First Submitted That Met QC Criteria

June 12, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 12, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • HFRN

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Withings Heart Function Risk Notification (HFRN)

Search Similar Trials